Venture Capital News: Breaking Venture Capital News, Comments and Articles. - Page: 4

20:18 EDT 25th October 2014 | BioPortfolio

Venture Capital News - Page: 4RSS

Read the latest Venture Capital News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Venture Capital.

Search or Follow Our Venture Capital - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Venture Capital - Page: 4 News.

Showing "venture capital" News Articles 76 to 100 of 7,700+

Thursday 23rd October 2014

Sverica International Announces Acquisition of Resonetics

Sverica International Management LLC (“Sverica”), a private equity investment firm, announced today that it acquired Resonetics, LLC (“Resonetics”) on October 21,, 2014. Resonetics is a leading supplier of laser micromachining solutions to the life sciences industry with a particular focus o

Enigma and Beijing Leadman Form Infectious Disease Diagnostic JV

Enigma Diagnostics of England announced a joint venture with Beijing Leadman Biochemistry for China development of Enigma's molecular diagnostic point-of-care (PoC) infectious disease test. Beijing Leadman will market the Enigma Mini Laboratory PoC m...

Resonetics Recapitalizes with Sverica International

NASHUA, N.H., Oct. 23, 2014 /PRNewswire/ -- Resonetics today announced that Sverica International has acquired the company from Corporate Fuel Partners. Resonetics will maintain its headquarters in Nashua, New Hampshire, and CEO Tom Burns and the current management team will remain in place. Terms of the transaction were not disclosed. Resonetics is a leading supplier of laser micromac...

HealthSouth To Build Hospital In Franklin, Tennessee

BIRMINGHAM, Ala., Oct. 23, 2014 /PRNewswire/ -- HealthSouth Corporation (NYSE: HLS) today announced that the Tennessee Court of Appeals has affirmed the order approving its certificate of need to build a 40-bed inpatient rehabilitation hospital in Franklin, Tennessee.    "We are pleased that the decision of the Health Services and Development Agency in Tennessee to approve our...

Enigma moves to bring molecular Dx platform to China

Enigma Diagnostics has entered into a joint venture with Beijing Leadman Biochemistry to offer the Enigma Mini Laboratory pla -More- 

Hyaluronic Acid Market (Glass Acid) - 9.14% CAGR Forecast Globally to 2018

DALLAS, October 23, 2014 /PRNewswire/ -- ReportsnReports.com adds Global Hyaluronic Acid (HA) Market 2014-2018 research report of 80 pages to the pharmaceuticals category of its online market research reports library. Global HA market can be divided on the basis of application into the following segments: Dermal Fillers, Osteoarthritis, Ophthalmic, and VUR. Complete report is available at http://...

Benchmark Electronics Results Exceed Third Quarter Guidance

ANGLETON, Texas, Oct. 23, 2014 /PRNewswire/ -- Benchmark Electronics, Inc. (NYSE: BHE), a leading integrated contract manufacturing provider, today announced financial results for the quarter ending September 30, 2014. Three Months Ended Sep 30, Jun 30,

GSK mulls $27 billion ViiV sell-off

After a difficult few years and another poor quarter, GlaxoSmithKline has announced that it is looking to float its fast-growing HIV drugs business ViiV Healthcare to help shore up its finances. The ViiV venture which is 80%-owned by GSK, with Pfizer and Shionogi owning the remaining 20%, has recently launched the HIV medicine Tivicay (dolutegravir), which has brought in strong sales. Image...

Silicon Valley VC Confidence Declines for First Time in Two Years

New research just released by University of San Francisco (USF) Professor Mark Cannice shows a drop in confidence levels of venture capitalists. The Q3 reading is the first recorded decline in confidence in two years. San Francisco, CA (PRWEB) October 23, 2014 The Silicon Valley Venture Capitalist Confidence Index® for the third quarter of 2014, based on a September 2014 survey of 33 San Fra...

BRIEF-Erytech Pharma raises 30 million euros in reserved capital increase

* Raises 30 million euros for expanding its therapeutic indications in oncology and accelerating its clinical development

ERYTECH Successfully Raises €30 Million for Expanding Its Therapeutic Indications in Oncology and Accelerating Its Clinical Developments

Reserved capital increased with €30 million, of which 68% subscribed by US investors specialized in life sciences Following its recent success in acute leukemia, ERYTECH intends to speed up its development in the USA and in solid tumors Regulatory News: ERYTECH (Paris:ERYP)(Euronext Paris: FR0011471135 - ER...

AkzoNobel to Sell its 50% Stake in Eka Synthomer JV

As a further step in its ongoing strategic portfolio review, AkzoNobel has announced plans to sell its half of the non-consolidated 50:50 joint venture Eka Synthomer to its Germany-based partner, Synthomer. Based in Finland, Eka Synthomer produces an...

Wednesday 22nd October 2014

WuXi PharmaTech and Foundation Partner to Offer Cancer Test in China

WuXi PharmaTech formed a collaboration with Foundation Medicine of Cambridge, MA that will offer the FoundationOne® assay in China. The assay tests for genetic abnormalities associated with cancer to determine the best treatment. For pharmas unde...

Auspherix Secures Additional AU$1million from MRCF to Advance Its Antibiotic Pipeline

Highly experienced team secured Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease has secured a further AU$1 million in a series A financing from Australia’s Medical Research Commercialisation Fund (MRCF), to progress its antibacterial compounds through development studies. ...

Figure 1: Venture financing for therapies and diagnostics for bacterial infections

Cover Story: Diagnosing resistance Figure 1. Venture financing for therapies and diagnostics for bacterial infections. (I) Total amount of venture financing for newly formed companies developing therapies or …

Akers Biosciences Announces Joint Venture to Market Rapid Diagnostic Tests in China

THOROFARE, N.J., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (LSE:AKR) (the "Company" or "Akers"), a leading designer and manufacturer of rapid diagnostic screening and testing products, has signed a Joint Venture Agreement (the "Joint Venture Agreement") with Hainan Savy Investment Management Ltd ("Hainan") and Mr. Thomas Knox ("Thomas Knox"), the Company's Non-execut...

Medifocus, Inc. Announces Its Sponsorship at the VM Medical 20th Anniversary Breast Cancer Conference October 23rd and 24th

COLUMBIA, MD and TORONTO, ON -- (Marketwired) -- 10/23/14 -- Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be a sponsor at the upcoming VM Medical 20th Anniversary Breast Cancer Conference held on October 23rd and 24th, 2014 in Montreal, Canada. In addition, Medifocus will present a Poster on its "Wide-Field Focused Microwave Thermotherapy in Combination wi...

Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2014

SALT LAKE CITY, UT -- (Marketwired) -- 10/23/14 -- In the third calendar quarter (3Q) and first nine months (9M) of 2014, Utah Medical Products, Inc.'s (NASDAQ: UTMD) changes in income statement results compared to the same time periods in the prior calendar year were as follows: Profit margins in 3Q 2014 and 9M 2014 compared to 3Q 2013 and 9M 2013 were as follows: Currencies in this re...

Critical Outcome Technologies Provides Summary of Recent Achievements and Future Milestones at Annual General Meeting

LONDON, ONTARIO -- (Marketwired) -- 10/23/14 -- Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT)(OTCQB: COTQF), the biopharmaceutical company using machine learning to rapidly develop targeted therapies, announced today that its President & Chief Executive Officer, Dr. Wayne Danter, provided a summary of the key business achievements during the past year and an overview of plans ...

Aurora Spine Announces Expansion of U.S. Hospital Network Through Agreement With MedAssets

CARLSBAD, CALIFORNIA -- (Marketwired) -- 10/23/14 -- Aurora Spine Corporation (TSX VENTURE: ASG) announced it has entered into a national contract with MedAssets. MedAssets is one of the nation's largest third-party providers of supply chain management and outsourced procurement capabilities. MedAssets manages, on behalf of its clients, more than $50 billion in supply expense per year through th...

Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin

BEVERLY, MA -- (Marketwired) -- 10/23/14 -- Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications, is pleased to announce positive top-line results for its Phase 2b randomized double-blind study comparing three dosing regimens of Brilacidin to daptomycin for the treatmen...

Stellar Biotechnologies and Biovest International Sign KLH Supply Agreement for BiovaxID Immunotherapy for Follicular Non-Hodgkin's Lymphoma

PORT HUENEME, CA -- (Marketwired) -- 10/23/14 -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) and Biovest International, Inc. ("Biovest") today announced that the companies have executed a definitive supply agreement to meet Biovest's requirements for Keyhole Limpet Hemocyanin (KLH) for use in Biovest's BiovaxID® active immunotherapy to treat foll...

Theravance to Report Third Quarter 2014 Financial Results on October 30, 2014

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/23/14 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended September 30, 2014 after market close on Thursday, October 30, 2014. An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. To participate in the live call by telephone, please dial (877) 837-3908 from the U....

Helix BioPharma Corp. Announces Fiscal 2014 Results

AURORA, ON -- (Marketwired) -- 10/23/14 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2014. HIGHLIGHTS The following are selected highlights during the 2014 fiscal year and subsequent to year-end: FINANCIAL REVIEW The Comp...

Fitch Affirms Presence Health's (IL) Revs at 'BBB+'; Outlook Stable

Fitch Ratings has affirmed the 'BBB+' rating on the following Illinois Health Facilities Authority and Illinois Finance Authority bonds issued on behalf of Provena Health and Resurrection Health Care as parity obligations under the Presence Health Network (Presence) indenture: --$96.1 million series 2010A (Legacy Provena Debt); --$200 mil...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks